| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Se... |
| 03 Nov 2026 |
Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
Sold 2,035 shares ($94K) |
| 03 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million — |
| 09 Oct 2026 |
Form 4: Reed Joshua, SVP, Chief Financial Officer
Received 9,164 shares by exercise or conversion · Gave up 4,069 shares to cover exercise price or tax ($163K) |
| 09 Oct 2026 |
Form 4: Whitaker Anne Clem, Director
Granted 7,239 Restricted Stock Unit Award · Granted 17,998 Non Qualified Stock Option (Right to Buy) |
| 02 Oct 2026 |
Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
Sold 2,034 shares ($83.5K) |
| 02 Oct 2026 | 144 |
| 21 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
| 18 Sep 2026 |
Form 3: Whitaker Anne Clem, Director
No securities owned |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive... |
| 03 Sep 2026 |
Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
Sold 2,034 shares ($97.7K) |
| 03 Sep 2026 | 144 |
| 01 Sep 2026 |
Form 4: Hopkinson Craig C., EVP R&D, Chief Medical Officer
Received 5,000 shares by exercise or conversion ($123K) · Sold 9,000 shares ($423K) |
| 01 Sep 2026 | 144 |
| 17 Aug 2026 |
Form 4: Nichols Christian Todd, SVP, Chief Commercial Officer
Sold 7,576 shares ($373K) |
| 17 Aug 2026 | 144 |
| 12 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
This Amendment No. 1 to Credit Agreement, dated as of August 12, 2026 (this “Amendment”), to the Credit Agreement, dated as of February 12, 2026 (as amended, restated, supplemented or otherwise modified from time to time prior to the dat... |
| 07 Aug 2026 |
Form 4: Jackson Blair Curtis, Director
Granted 217,534 Employee Stock Option (Right to Buy) |
Loading...